Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "IDS"

392 News Found

ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024
Clinical Trials | July 16, 2024

ViiV Healthcare to announce data from largest head-to-head randomised clinical trial for 2-drug regimen Dovato against 3-drug regimen Biktarvy at AIDS 2024

Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain


Evonik, University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery
News | February 18, 2024

Evonik, University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery

Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery


Lupin Life hosted Second Edition of Aptivate Champion Run for Kids
News | January 15, 2024

Lupin Life hosted Second Edition of Aptivate Champion Run for Kids

The Aptivate Champion Run witnessed an enthusiastic participation of over 4,000 Mumbaikars


Lupin launches second edition of Aptivate Champion Run for Kids
News | January 09, 2024

Lupin launches second edition of Aptivate Champion Run for Kids

Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in Aptivate Champion Run


Pharmaids Pharmaceuticals to acquire Adita Bio Sys in share swap
News | January 07, 2024

Pharmaids Pharmaceuticals to acquire Adita Bio Sys in share swap

The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company


Laurus Labs receives USFDA tentative approval for Dolutegravir 5mg and 10mg in HIV/AIDS treatment
Drug Approval | May 03, 2023

Laurus Labs receives USFDA tentative approval for Dolutegravir 5mg and 10mg in HIV/AIDS treatment

It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment


Evonik starts construction of new U.S. facility for pharmaceutical lipids
News | April 29, 2023

Evonik starts construction of new U.S. facility for pharmaceutical lipids

Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness


Evonik opens new facility for pharmaceutical lipids in Germany
News | March 09, 2023

Evonik opens new facility for pharmaceutical lipids in Germany

New GMP facility for clinical and small-scale commercial pharmaceutical lipids


Lupin launches Aptivate Champion Run for Kids
News | February 04, 2023

Lupin launches Aptivate Champion Run for Kids

Through this important initiative, Lupin Life encourages children from Mumbai, Thane, and Navi Mumbai to participate in the Aptivate Champion Run


Pfizer and BioNTech granted U.S. EUA for booster dose for kids 5-11 years
Drug Approval | May 18, 2022

Pfizer and BioNTech granted U.S. EUA for booster dose for kids 5-11 years

Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series